Anticancer Drugs from Marine Flora: An Overview by Sithranga Boopathy, N. & Kathiresan, K.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2010, Article ID 214186, 18 pages
doi:10.1155/2010/214186
Review Article
AnticancerDrugsfromMarine Flora: An Overview
N. SithrangaBoopathyandK.Kathiresan
Center of Advanced Study in Marine Biology, Faculty of Marine Sciences, Annamalai University, Parangipettai 608 502,
Tamil Nadu, India
Correspondence should be addressed to K. Kathiresan, kathirsum@rediﬀmail.com
Received 30 August 2010; Accepted 29 November 2010
Academic Editor: Dominic Fan
Copyright © 2010 N. Sithranga Boopathy and K. Kathiresan. This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Marine ﬂoras, such as bacteria, actinobacteria, cyanobacteria, fungi, microalgae, seaweeds, mangroves, and other halophytes are
extremely important oceanic resources, constituting over 90% of the oceanic biomass. They are taxonomically diverse, largely
productive, biologically active, and chemically unique oﬀering a great scope for discovery of new anticancer drugs. The marine
ﬂoras are rich in medicinally potent chemicals predominantly belonging to polyphenols and sulphated polysaccharides. The
chemicals have displayed an array of pharmacological properties especially antioxidant, immunostimulatory, and antitumour
activities. The phytochemicals possibly activate macrophages, induce apoptosis, and prevent oxidative damage of DNA, thereby
controlling carcinogenesis. In spite of vast resources enriched with chemicals, the marine ﬂoras are largely unexplored for
anticancer lead compounds. Hence, this paper reviews the works so far conducted on this aspect with a view to provide a baseline
information for promoting the marine ﬂora-based anticancer research in the present context of increasing cancer incidence,
deprived of the cheaper, safer, and potent medicines to challenge the dreadful human disease.
1.Introduction
Cancerisadreadfulhumandisease,increasing withchanging
life style, nutrition, and global warming. Cancer treatments
do not have potent medicine as the currently available drugs
are causing side eﬀects in some instances. In this context,
the natural products derived from medicinal plants have
gained signiﬁcance in the treatment of cancer. According to
the WHO, 80% of the world’s population primarily those
of developing countries rely on plant-derived medicines for
the health care [1]. Natural products and their derivatives
represent more than 50% of all the drugs in clinical use
of the world. Higher plants contribute not less than 25%
of the total. Almost 60% of drugs approved for cancer
treatment are of natural origin. Fruits and vegetables are
the principal sources of vitamins C, B, E, carotenoids, and
ﬁbers, and these contributeto theapparent cancer-protective
eﬀects of the foods. There is a positive correlation between
the increased dietary intake of natural antioxidants and the
reduced coronary heart diseases, cancer mortality, as well as
longer life expectancy [2, 3]. Herbal drug formulations for
the prevention and treatment of cancer appeared in the last
threedecades,andtheinterestonnaturalsourcesofpotential
chemotherapeutic agents is continuing.
Antioxidants play an important role in the later stages
of cancer development. There is increasing evidence that
oxidative processes promote carcinogenesis, although the
mechanisms for this are not well understood. The antiox-
idants may be able to cause the regression of premalig-
nant lesions and inhibit their development into cancer.
Preliminary studies have indicated that some antioxidants,
particularly β-carotene, may be of beneﬁt in the treatment
of precancerous conditionssuch as oral leukoplakia,possibly
a precursor of oral cancer [4]. Several herbs and spices
including rosemary, sage, thyme, nutmeg, turmeric, white
pepper, chilli, pepper, ginger, and plenty of other medicinal
plants are reportedly exhibiting antioxidant activity [5–7].
Majority of the active antioxidant compounds are ﬂavon-
oids,isoﬂavones,ﬂavones,anthocyanins, coumarins,lignans,
catechins, and isocatechins. In addition to these, vitamins
Ca n dE ,β-carotene, and α-tocopherol present in natural
foods, are known to possess antioxidant potential [8–10].2 Journal of Oncology
Thus, potential antioxidant and anticancer properties of
plant extracts or isolated products of plant origin can
possibly be explored for developing the anticancer drugs
[11].
From the past few decades, there has been an upsurge
in the search for new plant-derived drugs. This process has
facilitated to produce remarkably a diverse array of over
1,39,000 natural products, containing medicinally useful
terpenoid derivatives, alkaloids, glycosides, polyphenolics,
steroids, and so forth. The National Cancer Institute (NCI)
of the United States of America (USA) has screened about
1,14,000 extracts from an estimated 35,000 plant samples
against a number of tumor systems [12]. Of the 92 anti-
cancerdrugscommerciallyavailablepriorto1983intheUSA
and approved world-wide between 1983 and 1994, approx-
imately 62% can be related to natural origin [13]. Some
examples include vinblastine and vincristine (Catharanthus
roseus), epipodophyllotoxin, an isomer of podophyllotoxin
(Podophyllum peltatum roots), paclitaxel (Taxus baccata,
T. brevifolia, T. canadensis), camptothecin (Camptotheca
acuminata), homoharringtonine (Cephalotaxus harringtonia
var. drupacea), elliptinium (Bleekeria vitensis), ﬂavopiri-
dol (Dysoxylum binectariferum), and ipomeanol (Ipomoea
batatas). The two plant-derived natural products, paclitaxel
and camptothecin were estimated to account for nearly one-
third ofthe global anticancer market, respectively to the tune
of about $3 and $9 billion, in the year 2002 [14].
Numerous types of bioactive compounds have been
isolated from plant sources. Several of them are currently
in clinical trials or preclinical trials or undergoing fur-
ther investigation. Although marine compounds are under-
represented in current pharmacopoeia, it is anticipated that
the marine environment will become an invaluable source
of novel compounds in the future, as it represents 95% of
the biosphere [15]. However, development of marine ﬂoral
compounds as therapeutic agents is still in its embryonic
stage due to lack of an analogous ethno-medical history as
compared to terrestrial habitats, together with the relative
technical diﬃculties in collecting the marine ﬂoral samples.
Over the last few decades, signiﬁcant eﬀorts have been
made, by both pharmaceutical companies and academic
institutions, to isolate and identify new marine-derived,
natural products especially from faunal species. However,
the marine ﬂoras are only little unexplored and these works
a r er e v i e w e dh e r ea sab a s e l i n ed a t af o rp r o m o t i n gf u r t h e r
research in this ﬁeld.
2.Uniquenessof MarineFloralDrugs
Marine ﬂoras include microﬂora (bacteria, actinobacteria,
cyanobacteria and fungi), microalgae, macroalgae (sea-
weeds), and ﬂowering plants (mangroves and other halo-
phytes). Occupying almost 71% of globe, the ocean is rich
in biodiversity, and the microﬂora and microalgae alone
constitute more than 90% of oceanic biomass [16]. This vast
marine ﬂoral resource will oﬀera great scopefordiscovery of
new drugs. It is increasingly recognized that ocean contains
a huge number of natural products and novel chemical
entities with unique biological activities that may be useful
in ﬁnding the potential drugs with greater eﬃcacy and
speciﬁcityforthetreatmentofhumandiseases[17].Itcannot
be deniedthatwith 3.5 billionyears ofexistenceon earth and
experience in biosynthesis, the marine microﬂoras remain
nature’s best source of chemicals. The marine organisms
produce novel chemicals to withstand extreme variations in
pressure, salinity, temperature, and so forth, prevailing in
their environment, and the chemicals produced are unique
in diversity, structural, and functional features [18].
The eﬀorts to extract drugs from the sea started in
the late 1960s. However, the systematic investigation began
in the mid-1970s. During the decade from 1977 to 1987,
about 2500 new metabolites were reported from a variety of
marine organisms. These studies have clearly demonstrated
that the marine environment is an excellent source of novel
chemicals, not found in terrestrial sources. So far, more
than 10,000 compounds have been isolated from marine
organisms with hundreds of new compounds are still being
discoveredeveryyear. About300patentsonbioactive marine
natural products were issued between 1969 and 1999 [18].
Some marine organisms are proved to be the potent sources
ofdrugs.Thesearemostlyinvertebratesthatincludesponges,
soft corals, sea fans, sea hares, nudibranchs, bryozoans, and
tunicates. It is now believed that microbial ﬂoras present
in the invertebrates are responsible for the production of
medicinal compounds. The search is mostly conﬁned to
marine faunal species, and ﬂoral species are largely ignored.
Some of the compounds derived from marine organisms
have antioxidant property and anticancer activities, but they
are largely unexplored.
Marine ﬂoras have been used for medicinal purposes in
India, China, the Near East and Europe, since ancient times.
The people of China and Japan have been using seaweeds
for consumption. The seaweeds especially brown seaweeds
are rich in iodine and hence there is a least incidence of
goiter and glandular diseases. History reveals that maritime
countries have been using seaweeds as vermifuge, anesthetics
and ointment as well as for the treatment of cough, wounds,
gout,goiter,venerealdisease, andsoforth.Sterolsandrelated
compounds present in seaweeds have ability to lower blood
plasma cholesterol level. Seaweed dietary ﬁbers perform
variedrangeoffunctions suchasantioxidant,antimutagenic,
anticoagulant, and antitumor. The seaweeds also play an
important role in modiﬁcation of lipid metabolism in the
humanbody.Highintakeofcalcium,potassium,andsodium
is associated with lower mean systolic pressure and lower
risk of hypertension. All seaweeds oﬀer an extraordinary
level of potassium that is very similar to our natural plasma
level.Seaweed extract isinterestingly similar to human blood
plasma. Two Japanese surgeons have used a novel technique
of mixing seaweed compounds with water to substitute
whole blood in transfusion and this has been successfully
tried in over 100 operations [4].
Although, the use of seaweeds in medicine is not as
wide spread as once it was, the use of seaweed polymer
extract in pharmacy, medicine, and biochemistry is well
established. Clinical trials are also in progress to make
diabetic patients free from injection by introducing insulinJournal of Oncology 3
secreting“jellycapsule”madeofseaweed-derivedalginicacid
[19]. The capsule renders protection to white blood cells and
thepatient’simmune system.Seaweed gumslikecarrageenan
(extracted from red seaweed) or algin (from brown seaweed)
are rich sources of soluble ﬁbers [4].
3.AnticancerAgentsfromMarine Floras
3.1. Bacteria. Marine microorganisms are a source of new
genes, and exploitation of which is likely to lead to the
discovery of new drugs and targets. Secondary metabolites
produced by marine bacteria have yielded pharmaceutical
products such as novel anti-inﬂammatory agents (e.g., pseu-
dopterosins, topsentins, scytonemin, and manoalide), anti-
cancer agents (e.g., bryostatins, discodermolide, eleuther-
obin, and sarcodictyin), and antibiotics (e.g., marinone).
The contribution of probiotic bacteria, such as lactobacilli
and biﬁdobacteria, is mainly in the control of pathogenic
microbes, through production of antibacterial protein
namely, bacteriocin [20, 21] and anticancer substances
[22]. The dietary supplements of lactobacilli are reportedly
decreasing the induction of experimental colon cancer [23].
They stimulate and modulate the mucosal immune system
by reducing the production of proinﬂammatory cytokines
throughactionsonNFκBpathways,increasing productionof
anti-inﬂammatory cytokines such as IL-10 and host defense
peptides such as β-defensin 2, enhancing IgA defenses and
inﬂuencing dendritic cell maturation as well as modulation
of cell proliferation and apoptosis through cell responses to
short chain fatty acids [24].
Most of the marine animal phyla produce toxins and
some studiesshow thatthesemarine toxinsmay beproduced
by marine bacteria associated the animals [25–27]. The
microbial toxins are useful in neurophysiological and neu-
ropharmacological studies. For example, bacteria present in
Noctiluca scintillans are responsible for causing red tides. The
major metabolite, macrolactin-A, inhibits B16-F10 murine
melanoma cancer cells, mammalian herpes simplex virus
(HSV) (types I and II), and protects T lymphocytes against
human immunodeﬁciency virus (HIV) replication [28].
Kahalalide F (KF) is a depsipeptide isolated from the
mollusk Elysia rubefescens from Hawaii and the compound
is believed to be synthesized by microbes associated with the
animal. KF induces cytotoxicity and blocks the cell cycle in
G1 phase in a p53-independent manner. In vitro,K Fd i s p l a y s
activity against solid tumors with an interesting pattern of
selectivity in prostate cancer cell lines. In addition, extensive
invivoworkdemonstratesthattheagenthasactivityinbreast
and colon cancers.
Only a few marine bacteria can be isolated under
laboratory conditions and there is an urgent need to develop
new culture techniques to isolate slow-growing bacteria and
also to isolate the bacteria that are unique in production of
novel natural products [29].
3.2. Actinomycetes. For more than 50 years, the soil-derived
actinomycetes of terrestrial origin have provided a major
pharmaceutical resource for the discovery of antibiotics
and related bioactive compounds. However, marine actino-
mycetes received only very recent attention. Gutingimycin
is a highly polar trioxacarcin derivative from Streptomyces
species, isolated from sediment of the Laguna de Terminos,
Gulf of Mexico [30]. The same Streptomyces species also
yields trioxacarcins D–F, in addition to the known trioxacar-
cins A–C [30]. Among the antibiotic-producing microbes,
marine actinomycetes within the family Micromonospora-
ceae are very promising. These microbes are found to be a
potent sources of anticancer agents that target proteasome
function and their industrial potential is validated by several
pharmaceuticals.
Thiocoraline is a novel bioactive depsipeptide isolated
from Micromonospora marina, a marine microorganism
located in the Mozambique Strait that inhibits RNA syn-
thesis. The bioactive compound is also selectively cytotoxic
against lung and colon cancer cell lines as well as melanoma.
Interestingly, the compound exerts preferential antiprolif-
erative eﬀects in colon cancer cell lines with defective p53
systems [31]. Thiocoraline represents a model of an an-
ticancer agent acquired from marine microorganisms and
illustrates how the problems of drug supply can be overcome
by artiﬁcial culture.
3.3. Marine Fungi. A rich proﬁle of biologically active
metabolites is described from ﬁlamentous fungi of terres-
trial origin, especially from just three genera: Penicillium,
Aspergillus, and Fusarium [32]. However, the marine fungi
are least studied than terrestrial counterparts and other
ecological groups. Obligate marine fungi are still an unex-
plored resource, although, marine facultative fungi, have
been studied due to their production of new metabolites
which are not found in terrestrial fungi. Recently more
interest has been generated on studying biologically active
metabolites from higher fungi (Basidiomycetes), endophytic
fungi and ﬁlamentous fungi from marine habitats, the
symbiotic lichens.
In one study, the lignicolous fungus Leptosphaeria or-
aemaris (Pleosporaceae) yielded leptosphaerin [33, 34]. A
further study of the same fungal species yielded none
of the previously found metabolites, but the polyketides,
leptosphaerolide, its o-dihydroquinone derivative, and lep-
tosphaerodione [35]. This leads to a conclusion that the pro-
duction ofsecondary metabolites might be highly dependent
on the culture conditions and the origin of the strains. To
produce these metabolites and to maximize the potential
chemicaldiversity,theyneedtobegrowninvariousnutrient-
limited media. For example, media for Penicillium spp. that
are deﬁcient in carbon can produce penicillins, those that
are phosphorus-limited can produce cephalosphorins and
vancomycin,andthosethatarenitrogen-limited canproduce
carbapenems [36].
Marine-derivedfungi are knowntobe asource ofantiox-
idative natural products: (i) Acremonin A from Acremonium
sp. [37] and (ii) Xanthone derivative from Wardomyces
anomalus [38].Reactions offree radicals, suchas super-oxide
radical, hydroxyl radical, peroxyl radical and other reactive
oxygen and nitrogen are associated with diseases such as4 Journal of Oncology
atherosclerosis, dementia, and cancer. Antioxidants delay or
prevent oxidative damage and thus they may be useful as
therapeutics or food additives.
3.4. Micro Algae. Marine blue-green algae (Cyanobacteria)
are considered to be one of the potential organisms which
can be the richest sources of known and novel bioactive
compounds including toxins with potential for pharmaceu-
tical applications [39, 40]. Some of the marine cyanobacteria
appear to be potential sources for large-scale production of
vitamins (B complex, E) of commercial interest. Scytonemin
is a protein serine/threonine kinase inhibitor [41], isolated
from the cyanobacterium Stigonema sp. and this compound
is a yellow-green ultraviolet sunscreen pigment, known to
be present in the extracellular sheaths of diﬀerent genera
of aquatic and terrestrial blue-green algae. Scytonemin
regulatesmitoticspindle formationaswell asenzyme kinases
involved in cell cyclecontrol and the compound also inhibits
proliferationofhumanﬁbroblastsandendothelialcells.Thus
scytonemin may provide an excellent drug as protein kinase
inhibitors to have antiproliferative and anti-inﬂammatory
activities [42].
More than 50% of the marine cyanobacteria are poten-
tially exploitable for extracting bioactive substances which
are eﬀective in either killing the cancer cells by inducing
apoptotic death, or aﬀecting the cell signaling through
activation of the members of protein kinase-c family of
signaling enzymes. The cell extracts of Calothrix isolates
inhibitthegrowthin vitro ofa chloroquine-resistant strain of
the malarial parasite, Plasmodium falciparum, and of human
HeLacancer cellsin a dose-dependentmanner [43].Bioassay
directed fractions of the extracts have led to their isolation
and structural characterization of Calothrixin A (I) and B
(II),pentacyclicmetaboliteswithanindole[3, 2 – j]phenan-
thridine alkaloids which exert their growth inhibitory eﬀects
at nanomolar concentrations [43]. Another compound,
Curacin-A, isolated from the organic extracts of Curacao
collections of Lyngbya majuscula is an exceptionally potent
antiproliferative agent asit inhibits the polymerization of the
tubulin and it also displays the inhibitory activity selectively
on colon, renal, and breast cancer-derived cell lines [28].
Largazole is unique chemical scaﬀold with impressive
antiproliferative activity derived from Symploca sp. [44]. The
apratoxins are another class of cyanobacterial compounds
that inhibit a variety of cancer cell lines at nanomolar con-
centrations. The parental compound, apratoxin A, isolated
from a strain of Lyngbya boulloni shows cytotoxicity to an
adenocarcinoma [45]. The coibamide A is a compound
derived from a strain of Leptolyngbya [46], and it exhibits
signiﬁcant cytotoxicity against NCIH460 lung and mouse
neuro-2a cells. The cytotoxicity is a common mechanism of
action for many cyanobacterial compounds [47].
In recent times, the most signiﬁcant discoveries are of
borophycin,cryptophycin1& 8,andcyanovirin. Borophycin
is a boron-containing metabolite, isolated from marine
cyanobacterial strains of Nostoc linckia and N. spongiaeforme
var. tenue [48]. The compound exhibits potent cytotoxicity
against human epidermoid carcinoma (LoVo) and human
colorectal adenocarcinoma (KB) cell lines [49]. Borophycin
is related both to the boron containing boromycins isolated
from a terrestrial strain of Streptomyces antibioticus and
to the aplasmomycins isolated from a marine strain of
Strepetomyces griseus (actinomycetes) [48].
Cryptophycin 1 was ﬁrst isolated from Nostoc sp. ATCC
53789 by researchers at Merck and found to be a potent
fungicide. As it was highly toxic, it was disregarded as a
natural productlead. Subsequently,the same compound iso-
lated from Nostoc sp. GSV 224 exhibited potent cytotoxicity
against human tumor cell lines and good activity against a
broad spectrum of drug sensitive and drug-resistant murine
and human solid tumors [50]. Nevertheless, cryptophycin 1
again appears to be too toxic to become a clinical candidate.
This leads to a detailed structure-function study which has
resulted in the isolation of cryptophycin 8, a semisynthetic
analogue with greater therapeutic eﬃciency and lower
toxicity than cryptophycin 14 in vivo [51]. Although neither
cryptophycin, nor any of its analogues have entered clinical
trails to-date, but interest in these compounds continues.
3.5. Macro Algae (Seaweed). Seaweeds are important sources
of protein, iodine, vitamins, and minerals and hence, their
metabolites have shown promising activities against cancer
incidences [52]. The seaweeds also contain high amounts
of polyphenols such as catechin, epicatechin, epigallocate-
chin gallate, and gallic acid, as reported in Halimeda sp.
(Chlorophyceae) [53]. In the past three decades, many
researchers have worked on the antioxidant, antitumor,
and immunomodulating activities of seaweeds [54]. Edible
seaweedlikePalmaria palmateisshowntobeeﬀectiveantiox-
idant, capable of inhibiting cancer cell proliferation [55].
The alcoholic extract of the red alga Acanthophora spicifera
exhibits tumoricidal activity on Ehrlich’s ascites carcinoma
cells developed in mice at a dose of 20mg/kg, comparable
to the standard drug, 5-ﬂurouracil. This is evidenced by
increase in the mean survival time, decrease in tumor
volume, and viable cell count. The smear study exhibits
membrane blebbing, vacuole formation, and reduction in
staining intensity, which further ascertains the tumoricidal
activity.The seaweedsAcanthaphoraspicifera, Ulvareticulata,
Gracilaria foliifera, and Padina boergesenii of the Gulf of
Mannar region are reportedly exhibiting cytotoxic activity in
their alcoholic extracts [56, 57].
Algae have gained special interest owing to their biologi-
cal properties. There are many reports on the immunomod-
ulating and antitumor activities of algae [54, 58–71]. An
extract from the brown seaweed Sargassum thunbergii has
shown antitumour activity [72] and inhibition of tumour
metastasis in the rat mammary adeno carcinoma cell (13762
MAT) [73]. Moreover, low-molecular weight fucoidan iso-
lated from Ascophyllum nodosum shows an anti-proliferative
eﬀect on both normal and malignant cells, including
ﬁbroblasts (Hamster Kidney Fibroblast CCL39), sigmoid
colon adenocarcinoma cells (COLO320 DM), and smooth
muscle cells [74]. Fucoidans exhibit antitumour, anticancer,
antimetastatic, and ﬁbrinolytic properties in mice [73, 75].
Stylopoldione, isolated from Stypodium sp. is a potentJournal of Oncology 5
cytotoxic metabolite, which halts mitotic spindle formation
[76]. The compound Condriamide-A from Chondria sp.
exhibits cytotoxicity towards human nasopharyngeal and
colorectal cancer cells [77]. Caulerpenyne from Caulerpa sp.
shows its bioactivity against human cell lines and to have
anticancer, antitumour, and antiproliferating properties.
Two compounds, meroterpenes and usneoidone, showing
antitumour properties have been isolated from Cystophora
sp. [78–81] Phloroglucinol and its polymers, namely, eckol
(atrimer), phlorofucofuroeckolA(apentamer), dieckol,and
8,8 -bieckol (hexamers) isolated from the brown alga Eisenia
bicyclis are shown to have antioxidant activity [82, 83].
The brown alga Eclonia cava has been hydrolyzed by
using ﬁve diﬀerent types of carbohydrases such as AMG,
Celluclast, Termamyl, Ultraﬂo, and Viscozyme to produce
enzymatic extracts and proved them to be potential natural
water-soluble antioxidants with dose dependent radical
scavenging activities [94]. Further studies have shown that a
sulfated polysaccharide puriﬁed from the same algal species
selectivelyanddose-dependentlysuppressestheproliferation
of the cancer cell lines in vitro [95]. The polysaccharide
is composed of fucose (82%), galactose (14%), and small
amountsofxyloseandmannose. Itshighanticoagulantactiv-
ity has also been investigated for its antiproliferative eﬀecton
murine colon carcinoma (CT-26), human leukemic mono-
cyte lymphoma (U-937), human promyelocytic leukemia
(HL-60),and mouse melanoma (B-16)cell lines. The growth
inhibition rate of CT-26 cells increases consistently with the
sample concentration, in which the highest activity (around
40%) is recorded at 100μgm L −1 sample [95]. The apoptosis
induction is conﬁrmed by the cell cycle analysis, while
pronounced sub-G1 phase arrests of 9.5% and 13.8% are
also clearly observed when the cells are treated at 15 and
30μgm L −1 of the sulphated polysaccharides in the U-937
cell line. The compound dose dependently enhances the
DNA fragmentation on the U-937 cell line as observed after
24-h incubation. The western blot analyses conducted with
several antibodies such as caspase-7, caspase-8, Bax, Bcl-xL,
and PARP and ECSP have exhibited a clear eﬀect on the
caspase-7 and -8 which cleave protein substrates, including
PARP, an inducer of apoptosis responsible for DNA cleavage
[95].
3.6. Mangroves and Other Higher Plants. Mangroves have
long been used in ﬁsher-folk medicine to treat diseases
[96, 97]. Sixteen plants are the possible source of anticancer
drugs, based on traditional knowledge and preliminary
scientiﬁc work (Table 1). A sulphur containing alkaloid,
1,2-dithiolane (Brugine) isolated form Bruguiera sexan-
gula displays antitumor activity against Sarcoma 180 and
Lewis. Tannin from the same plant also exhibits anticancer
activity against lung carcinoma. A ribose derivative of 2-
Benzoxazoline isolated from Acanthus ilicifolius shows anti-
cancer and antiviral activities [98]. Tea from the mangrove
plant Ceriops decandra is shown to successfully prevent the
dimethyl benz[a]anthracine-induced hamster buccal pouch
carcinogenesis; consequently it enhances beneﬁcial bacteria
like lactobacilli in oral cavity of the animals [88].
4.ChemicalConstituentsofMarineFlora
Marine ﬂoras are rich in biologically active and medic-
inally potent chemicals. Polyphenols and polysaccharides
are the most predominant group of compounds which are
applicable for antioxidant and anticancer activities. There
are more than 40,000 diﬀerent species of phytoplankton,
680 species of marine algae belonging to Rhodophyta,
Phaeophyta, Chlorophyta commonly known as red, brown,
and green seaweeds, respectively, and 71 mangrove plant
species have been documented in the global marine biotope.
They provide essential fatty acids, ionic trace minerals,
vitamins, enzymes, bioﬂavonoids, amino acids, and other
nutrients.
4.1. Polyphenols. Polyphenols are widely distributed in
plants and they are reportedly acting as free radical
scavengers, antimicrobial and anticancer agents [99, 100].
Marine plants such as seaweeds, sea grass, and mangroves
also contain high amounts of polyphenols such as phenolic
acids, ﬂavonoids, anthocyanidins, lignin, tannins, catechin,
epicatechin, epigallocatechin, and gallic acid [53, 101].
These polyphenolic compounds have shown many health-
beneﬁting bioactivities, such as antioxidant, anticancer,
antiviral, anti-inﬂammatory, and an ability to inhibit human
platelet aggregation [102–104]. Some studies have shown
a positive correlation between the increased dietary intake
of natural antioxidants and the reduced coronary heart
disease, cancer mortality, as well as longer life expectancy
[2, 3]. Moreover, they are natural metal chelators with
high antioxidant activity that may be successfully used
to prevent a variety of toxic metal ion-induced organ
dysfunctions [105]. Earlier reports suggest that polyphe-
nols may regenerate α-tocopherol through reduction of
the α-tocopheroxyl radical [106]. A close association be-
tween anticarcinogenic activity and antioxidant activity
has been reported in a chemically induced mouse carci-
noma system with low-molecular weight polyphenols [107–
110].
T h em a r i n er e da l g a el i k eOsmundea pinnatiﬁda has
been documented for its antimicrobial, antifungal, anti-
leishmanial, and antioxidant [111–114] activities. Scutel-
larein 4 -methyl ether (Figure 1(a)) has antiallergic [115],
anticancer and anticytotoxic activities in vitro and in vivo
[116].
Terrestrial and marine polyphenols are similar in some
respects, but diﬀerent fundamentally in their chemical
structures. Terrestrial polyphenols are polymers based on
ﬂavonoids or gallic acids. Marine algal polyphenols, phloro-
tannins, which are only known in brown algae, are restricted
to polymers of phloroglucinol (1,3,5-trihydroxybenzene)
[117]. Six phlorotannins have been detected by HPLC
analysis in the brown seaweeds, Eisenia bicyclis and Eclonia
kurome, and they are phloroglucinol (0.7%), an unknown
phloroglucinol tetramer (MW 478, 3.4%), eckol (7.5%),
phlorofucofuroeckol A (21.6%), dieckol (21.9%), 8,8 -
bieckol (24.0%), and other unknown compounds (20.9%),
in E. bicyclis, and these compounds are also present in6 Journal of Oncology
Table 1: Some of the marine ﬂoral derivatives and their anticancer activities.
Marine ﬂora Chemical Biological activity Reference
Microbial ﬂora
Microcystis aeruginosa MicroviridinToxin BE-4, Siatoxin Antibiotic, anticancer [84, 85]
Streptomyces peucetius Daunorubicin Anticancer activities on acute myeloid leukemia and
acute lymphocytic leukemia [86]
Algal ﬂora
Cyanobacteria Nostoc
linckia and Nostoc
spongiaeforme var.
tenue
Borophycin Cytotoxicity against human epidermoid carcinoma
(LoVo)andhumancolorectaladenocarcinomaactivity [48]
Cyanobacteria Apratoxins Inhibit a variety of cancer cell lines [45]
Nostoc linckia Cyptophycin 1 Cytotoxicity against human tumor cell lines and hu-
man solid tumors [50]
Nostoc spongiaeforme Cryptophycin 8 Greater therapeutic eﬃciency and lower toxicity than
cryptophycin 14 in vivo [51]
Stylopodium sp. Stypoldione Cytotoxic [76]
Chondria sp. Condriamide A Cytotoxicity [77]
Caulerpa sp. Caulerpenyne Cytotoxicity, anticancer, antitumour, and antiprolifer-
ating activity [78–80]
Cystophora sp. Meroterpenes and Usneoidone Antitumour [81]
Symploca sp. Largazole Antiproliferative activity [44]
Lyngbya boulloni apratoxin A Cytotoxicity to adenocarcinoma [45]
Leptolyngbya sp. coibamide A Cytotoxicity againstNCIH460 lung and mouse neuro-
2a cells [46]
Stigonema sp. Scytonemin Antiproliferative and anti-inﬂammatoryactivities [41]
Acanthophora spicifera Crude Tumoricidal activity on Ehrlich’s ascites carcinoma
cells developed in mice [56, 57]
Acanthophora spicifera Crude Antioxidants and inhibiting cancer cell proliferation [56, 57]
Palmaria palmata
Phloroglucinol and its polymers, namely,
eckol (a trimer), phlorofucofuroeckol A
(a pentamer), dieckol, and 8,8 -bieckol
(hexamers)
Antioxidant activity of the phlorotannins [55]
Eisenia bicyclis
Phloroglucinol and its polymers, namely
eckol (a trimer), phlorofucofuroeckol A
(a pentamer), dieckol, and 8,8 -bieckol
(hexamers)
Antioxidant activity of the phlorotannins [82, 83]
Sargassum thunbergii Crude Antitumour activity, inhibition of tumour metastasis
in rat mammaryadeno carcinoma cell (13762 MAT) [72, 73]
Ascophyllum nodosum Fucoidan Antiproliferativeantitumour,anticancer,antimetastat-
ic, and ﬁbrinolytic [74, 75]
Mangroves and other coastal plants
Ceriops decandra Lignins Antioxidant [87]
Ceriops decandra Mangrove tea Anticancer [88]
Acanthus ilicifolius Ribose derivatives of benzoxazoline Anticancer [89, 90]
Calophyllum
inophyllum
Xanthone, biﬂavonoids, benzophenones,
neoﬂavanoids,and coumarin derivatives Anticancer, antitumour, and lipid peroxidation [91, 92]
Excoecaria agallocha
Diterpenes exhibited remarkable antitu-
mour promoting activity in vivo on two-
stage carcinogenesis test of tumour
Antitumour activity of methanolic extract based on
three assays: (i) DPPH radical scavenging, (ii) linoleic
acid oxidation assay,and (iii) oxidative cell death assay
[93]Journal of Oncology 7
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Figure 1: Anticancer polyphenolic compounds from marine ﬂoras.
E. kurome, respectively, at concentrations of 2.2, 0.6, 8.5,
27.6, 23.6, 6.8, and 31.7% (Figures 2(b), 2(c), 2(d), 2(e),
and 2(f)). The crude phlorotannins extracted from brown
algae have inhibitory eﬀects on HAase [118]. The half
maximal inhibition (IC50) values of crude phlorotannins
of E. bicyclis and E. kurome, two terrestrial polyphenols
(catechin, EGCG), inhibit four times stronger than that by
an anti-allergic drug (DSCG) [119].8 Journal of Oncology
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Figure 2: Anticancer polysaccharides from marine ﬂoras.
Edible seaweeds contain a range of potentially bioactive
componentsincludingpolyphenolsandphlorotannins [120–
123]. Edible seaweed like Palmaria palmate is shown to be
an eﬀective antioxidant, capable of inhibiting cancer cell
proliferation [55]. The enzymatic hydrolysis of the brown
seaweed Ecklonia cava yields high amount of compounds
with enhanced biological activities as compared with water
andorganic extract counterparts [94].Phloroglucinol andits
polymers, namely, eckol (a trimer), phlorofucofuroeckol A
(a pentamer), dieckol, and 8,8 -bieckol (hexamers) isolated
from Eisenia bicyclis, have a potential antioxidant activity
[82]. The phlorotannins isolated from Ecklonia kurome act
as antiplasmin inhibitor; however, other bioactivities of
phlorotannins, from a human physiological viewpoint, are
still obscure [124].
Polyphenolic compounds inhibit cancer cells by xenobi-
otic metabolizing enzymes that alter metabolic activation of
potential carcinogens, while some ﬂavonoids can also alter
hormone production and inhibit aromatase to prevent the
development of cancer cells [125]. The mechanism of action
ofanticanceractivityofphenolicsisbydisturbingthecellular
division during mitosis at the telophase stage. Phenolics
reduce the amount of cellular protein and mitotic index, and
the colony formation during cell proliferation of cancer cells
[126]. Several studies exhibit a close relationship between
antioxidant activities and total phenolic content [127–129].
Use of phytosubstances to improve or enhance their
eﬀects with safety in foods is signiﬁcantly focused in daily
food. The activities of diverse constituents vary in their
ability by quenching eﬀects against active free radical oxygen
by carotenes and cryptoxanthins, and polyphenols and
ﬂavonoids, by inhibition of absorption into small intestine
by dietary ﬁbres, or by regulation on eﬄuxand inﬂux ofions
in cell membranes by minerals to inhibit tumors [130–132].
The uses of saponins are natural detergents, well known
to primitive people as ﬁsh poisons. The interesting phar-
macological properties associated with the Chinese drug
“giwieng” are considered a panacea and other interesting
biological activities such as spermicidal [133], molluscicidal
[134], antimicrobial, anti-inﬂammatory, and cytotoxicactiv-
ities [135]. Avicennia oﬃcinalis produces pharmacologically
signiﬁcant steroidal saponins, sapogenisis, and sapogenins.Journal of Oncology 9
Liomonds (modiﬁed terpenes) have attracted much atten-
tion recently because of their remarkable insect antifeedent
and growth-regulating activities [136]. There are many types
of ﬂavonoidssuch as ﬂavones, catechins, chalcones, ﬂavanols
and isoﬂavonoids which exhibit antioxidant activity towards
a variety of oxidizable compounds [137].
4.2. Polysaccharides. Over the last few years, medical and
pharmaceutical industries have shown an increased inter-
est in seaweed-derived polysaccharides. Polysaccharides or
glycans are a group of major chemical compounds with
the most common constituents of monosaccharide like
D-glucose, but D-fructose, D-galactose, L-galactose, D-
mannose, L-arabinose, and D-xylose are also frequently
present. Some monosaccharide derivatives found in polysac-
charides include the amino sugars (D-glucosamine and D-
galactosamine) as well as their derivatives (N-acetylneura-
minic acid and N-acetylmuramic acid) and simple sugar
acids (glucuronic and iduronic acids). Polysaccharides of
algal origin include alginates, agar, and carrageenans. Agar is
anunbranchedpolysaccharidepresentinthecellmembranes
of red algae, primarily from the genera Gelidium and
Gracilaria, and it is the primary structural support for the
algalcellwalls.Chemically,itisconstitutedbygalactosesugar
molecules. Carrageenans are polysaccharides of galactan
with alternating 1,3- and 1,4-linked galactose residues,
which ﬁll spaces between the cellulosic plant structure of
seaweeds.
The active components contained in algal polysaccha-
rides are mainly sulfated ones [63–67, 69, 70]. Most studies
support that sulfated polysaccharides can enhance the innate
immune response by promoting the tumoricidal activities
of macrophages and natural killer cells [138–141]. Antigen-
presenting cells migrate into and out of tumour tissue to
present tumour antigen to T-helper cells, as well as to
produce cytokines, such as interleukin-1 beta and TNF-
alpha that stimulate T-helper cells. As a result, T-helper cells
promote the activity of cytotoxic T-cell, which has the strong
cytotoxiceﬀectontumourcells. Sulfatedpolysaccharidescan
enhance the adaptive immune response by promoting such
process [140, 142–144]. Recent studies have implicated that
sulfated polysaccharides recognize a range of cell adhesion
systems. Sulfated polysaccharide can bind to CD2, CD3,
and CD4 in T lymphocytes and enhance the proliferative
response of T lymphocytes [145–147]. B-1, a sulfated
polysaccharide isolated from the culture ﬁltrate of marine
Pseudomonas sp., induces apoptosis of human leukaemic
cells (U937) [148]. PI-88, a sulfated oligosaccharide, induces
apoptosis of pancreatic islet carcinoma [149]. Internalized
sulfated glycosaminoglycans interfere with transcription
function and subsequently induce apoptosis of murine
melanoma cells [150].
Fucoidan is one of the representative sulfated polysac-
charides (sulphated L-fucose) derived from cell wall of
brown algae [65, 66, 151]. Fucoidan-induced apoptosis in
human lymphoma HS-Sultan cell lines is accompanied by
the activation of caspase-3 and down-regulation of extracel-
lular signal-regulated kinase pathway [152]. Fucoidans have
diverse biological properties, ranging from relatively simple
mechanical support functions to more intricate eﬀects on
cellular processes [151] and binding proteins such as adhe-
sion proteins [153], growth factors [154], cytokines [155],
and a variety of enzymes, including coagulation proteases
[156]. As a result, they can participate like glycosaminogly-
cans (GAGs) in cell adhesion, migration, proliferation, and
diﬀerentiation. They can also modulate clinically relevant
phenomena such as angiogenesis, tumor metastasis, and
atherosclerosis [157]. For the past decade, fucoidans isolated
from diﬀerent species have been extensively studied due
to their varied biological activities, including anticoagulant,
antithrombotic, antivirus, antitumor, immunomodulatory,
anti-inﬂammatory, blood lipids reducing, antioxidant, and
anticomplementary activities against hepatopathy, uropathy
and renalpathy, gastric protective eﬀects, and therapeutic
potential in surgery. Compared with other sulfated polysac-
charides, fucoidans have been increasingly investigated in
recent years to develop the drugs or functional foods [158].
The type of fucoidan, its sulphation and molecular weight,
and the conformation of its sugar residues vary with the
seaweed species [151, 159].
Sulphation is critical for fucoidan activity in vivo.I np a r -
ticular,desulphatedfucoidanfailstopromoteangiogenesisin
vitro [160] or to induce immature CD34+ cell mobilization
in vivo [161]. Native fucoidan-induced mobilization is abol-
ished in the presence of protamine [162]. The predominant
sulphation pattern consists of a trisulphated disaccharide
repeat similar to that found in heparin [163, 164]. Yet
heparin has no eﬀect on angiogenesis induced by HUVEC in
vitro[165] and doesnot inducesigniﬁcant immature CD34+
cell mobilization [161]. Furthermore, heparan sulphate
(Figure 2(b)), pentosan sulphate (Figure 2(c)), and chon-
droitin sulphate (Figures 2(d) and 2(e)), which exhibit anti-
coagulant activities, inhibit angiogenesis in vitro. Fucoidan
can disrupt heparan sulphate-growth factor/cytokine com-
plexes and can substitute for cell-surface heparan sulphates
in stabilizing the growth factor/growth factor receptor
interaction. Fucoidan may mediate growth factor-induced
EPC diﬀerentiation by interacting with a “receptor” that
promotes endothelial cell adhesion, migration, proliferation
and diﬀerentiation, and that cooperates with a growth factor
receptor, transducing the intracellular signals required to
induce the angiogenic phenotype. This putative fucoidan
receptor might contain a carbohydrate-binding domain
that interacts with the fucoidan carbohydrate backbone
[157].
4.2.1. Alkaloids. The term alkaloid was ﬁrst proposed by
Meissner in 1819 to characterize these “alkali-like” com-
pounds found in plants [166] ,b u ti tw a sn o tp r e c i s e l y
deﬁned [167]. With time, the deﬁnition has changed [168]
to a compound that has nitrogen atom(s) in a cyclic
ring. Numerous biological amines and halogenated cyclic
nitrogen-containing substances are included in the term
alkaloid. The latter could not be found in terrestrial plants
and is speciﬁc from marine organisms including marine
algae. Alkaloid chemistry and its anticancer activities have10 Journal of Oncology
been widely studied in terrestrial plants, but the number
of studies in marine plants are insigniﬁcant. Morphine was
the ﬁrst alkaloid extracted from a terrestrial plant in 1805
as reported by Kappelmeier [169], and hordenine was the
ﬁrst alkaloid isolated from marine algae in 1969 [170, 171].
Today approximately two thousand alkaloids are known.
They occur abundantly in terrestrial plants and rarely in
marine algae.
Among several types of compounds obtained from
plants, alkaloids have traditionally been of interest due to
their pronounced physiological activities in animals and
humans [172]. The most famous examples of anticancer
alkaloids are taxol (clinically available since 1994) from
the western yew, Taxus brevifolia,a n dc a m p t o t h e c i na n d
derivatives, currently in clinical trials, from Camptotheca
acuminata [14, 173, 174]. The alkaloidtaspine hydrochloride
founded in Sangre de Grado plant is also considered a
potentialanticanceragent[175],andhomoharringtonine, an
alkaloidisolated from theChinesetree Cephalotaxus harring-
tonia (Cephalotaxacea), has shown eﬃcacy against various
leukemias [176]. The isolation of vinca alkaloids such as
vinblastine and vincristine from the Madagascar periwinkle,
Catharanthus roseus G. Don. (Apocynaceae), has opened a
new era of the use of alkaloids as anticancer agents. They
w e r et h eﬁ r s ta g e n t se n t e r e dt oc l i n i c a lu s ef o rt h et r e a t m e n t
of cancer [177]. Vinblastine and vincristine are primarily
used in combination with other cancer chemotherapeutic
drugs for the treatment of a variety of cancers, including
leukemias, lymphomas, advanced testicular cancer, breast
and lung cancers, and Kaposi’s sarcoma [177].
The alkaloids found in marine algae may be divided into
three groups: Phenylethylamine alkaloids, Indole and halo-
genated indole alkaloids, and other alkaloids. Structurally,
the alkaloids isolated from marine algae mostly belong to
thephenylethylamine and indolegroups.Biologicalactivities
of these alkaloids were not fully investigated. Alkaloids of
marine algae are relatively rare, when compared with terres-
trial plant alkaloids. Research on marine drugs has largely
focused on ﬁnding drugs for cancer treatment. There are two
derivatives: lophocladine A (Figure 2(f)) and lophocladine
B( Figure 2(g)) isolated from a red alga Lophocladia sp.,
collected from Fijian Island, New Zealand [178]a n dt h e i r
anticancer activity has been proved successfully in various
cancer cell lines [168].
Coastal mangroves do contain alkaloids of anticancer
activity [98]. “Rhizophrine” is an alkaloid, a major con-
stituent of the leaves of Rhizophora mucronata and R. stylosa.
Similarly the presence of acanthicifolin in Acanthus illici-
folius, brugine (a sulphur containing alkaloid; Figure 3(a))
in Bruguiera sexangula, and benzoquinones (Figure 3(b))
in Aegiceras corniculatum and Kandelia kandel has been
recorded.
5.MechanismsfortheAnticancerActivityof
Marine Plants
DNA damage is considered to be one of the most important
steps leading to cancer. A marker of mutagenicDNAdamage
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Figure 3: Anticancer alkaloids from marine ﬂoras.
will be useful in the estimation of cancer risk of various pop-
ulations and in monitoring the eﬀects of chemoprevention.
Much of this damage is oxidative in nature. It is estimated
that a typical human cell experiences about 10.000 oxidative
“hits” to its DNA each day. DNA repair enzymes remove
most of the damage. Oxidative lesions to DNA accumulate
with age and so does the risk of cancer [4].
Antioxidants. Several mechanisms are defending against
free radicals and other reactive oxygen species (ROS) in
human system. Various defenses are complementary to one
another because they act on diﬀerent oxidants or in diﬀerent
cellular compartments. One important line of defense is a
system of enzymes, including superoxide dismutase (SOD),
glutathione peroxidase (GPx), and catalase as well as several
exogenously acquired radical-scavenging substances such
as vitamins E and C and carotenoids [179]. Under normal
conditions, the high concentrations of SOD maintain
superoxide concentrations at a level too low to allow the
formation of peroxynitrite. It is also important to mention
that the antioxidant reduces glutathione (GSH). GSH is
ubiquitous in aerobic tissues, and although it is not a
nutrient, it is synthesized from sulfhydryl-containing amino
acids and is highly important in intermediary antioxidant
metabolism [180]. Nutrition plays a key role in maintaining
the body’s enzymatic defences against free radicals. Several
essential minerals including selenium, copper, manganese,
and zinc are involved in the structure or catalytic activity of
these enzymes [180].
Unlike other vitamins, vitamin E is not shown to be
directly associated with the function of any enzyme system
[181]. Its only established role is that of an antioxidant
and a scavenger of free radicals, making it eﬀective as a
protector of the integrity of lipids and phospholipid mem-
branes. As an antioxidant, vitamin E is strongly interactive
with other dietary systemic antioxidants such as vitamin
C and glutathione. Accumulating evidence suggests that
vitamin E may have several other functions, including
modulation of gene expression and inﬂammatory responses
[182].
VitaminCisapowerfulantioxidantbecauseitcandonate
ah y d r o g e na t o ma n df o r mar e l a t i v e l ys t a b l ea s c o r b y lf r e e
radical (i.e., L-ascorbate anion). As a scavenger of ROS,
ascorbate is shown to be eﬀective against the superoxide
radical anion, hydrogen peroxide, the hydroxyl radical,
and singlet oxygen [183, 184]. Vitamin C also scavenges
reactive nitrogen oxide species to prevent nitrosation ofJournal of Oncology 11
target molecules [185] .T h ea s c o r b y lf r e er a d i c a lc a nb e
converted back to reduced ascorbate by accepting another
hydrogen atom or it can undergo further oxidation to
dehydroascorbate. Dehydroascorbate is unstable but is more
fat soluble than ascorbate and is taken up 10–20 times
more rapidly by erythrocytes, where it will be reduced
back to ascorbate by GSH or NADPH from the hexose
monophosphate shunt [186]. Thus, mechanism exists to
recycle vitamin C, which is similar to vitamin E.
Free radicals are a product of tissue metabolism, and the
potential damage which they can cause is minimized by the
antioxidant capacity and repair mechanisms within the cell.
Thus in a metabolically active tissue cell in a healthy subject
with an adequate dietary intake, damage to tissue will be
minimal and most of the damage, if it does occur, will be
repaired [187].Despitethefactthatthemarineplantspossess
application in food and in the pharmaceutical industry, the
antioxidant and anticancer activities of many types of plants
are still unexplored.
Immunomodulation and Apoptosis. Apoptosis is a complex
process that involves many diﬀerent signaling pathways and
results in a multitude of changes in the dying cells. The
apoptotic machinery is triggered as a result of a shift in the
balance of anti- and proapoptotic proteins. Up regulation
of antiapoptotic proteins, down regulation of proapoptotic
proteins, and decreased expression of caspases may lead
to decreased apoptosis. Evasion of apoptosis is recognized
to facilitate cancer development by blocking diﬀerentia-
tion, promoting angiogenesis, and increasing cell motility,
invasion, and metastasis [188]. Dysregulation of apoptotic
signaling can play a vital role in diseases with insuﬃcient
apoptosis leading to cancer.
The proapoptotic member of the Bcl-2 family such as
Bim, a BH3 induces apoptosis by binding to and inhibiting
the function of antiapoptotic proteins such as Bcl-XL and
Bcl-w. In addition, Bim is reportedly inducing cytochrome
C release from the mitochondria [189]. The release of cyto-
chrome C from the mitochondria is also induced by caspase
8, an initiator caspase that links the death receptor and
mitochondrial pathwaysofapoptosis.Caspase 3isaneﬀector
caspase that executes cell death by cleavage of proteins, vital
for cell survival [190].
Induction of apoptosis is one of the active strategies to
arrest proliferation of cancer cells. Radiation and chemical
agents like tamoxifen, capable of inducing apoptosis, have
been used to treat cancer [191, 192]. Many chemopreven-
tive agents exert their anticarcinogenic eﬀects by inducing
apoptosis [193]. The apoptosis inducing eﬀect of plant
extracts may be attributed to up regulated immune surveil-
lance, increased macrophage, and activations of death-
inducing signal complex. Natural dietary constituents such
as curcumin and resveratrol have been reported to induce
apoptosis in malignant cells in vitro [194] .T h em a r i n ep h y -
tochemicals also can activate the macrophages and induce
apoptosis. Fucoidan from Laminaria japonica can restore
the immune functions of immunosuppressed mice, and it
is an immunomodulator acting directly on macrophage and
Tl y m p h o c y t e[ 195]. It can also promote the recovery of
immunologic function in irradiated rats. The mechanism
is associated with the arrest of lymphocyte apoptosis by
fucoidan [196, 197]. Fucoidan can induce the production
of interleukin-1 (IL-1) and interferon-γ (IFN-γ) in vitro.I t
enhances the functions of T lymphocyte, B cell, macrophage,
and natural killer cell (NK cell) and also promotes the
primary antibody response to sheep red blood cell (SRBC)in
vivo [198]. High molecular-weight fucoidan prepared from
Okinawa mozuku promotes an increase in the proportion
of murine cytotoxic T cells [199]. Fucoidan from Fucus
vesiculosus has immunostimulating and maturing eﬀects on
dendritic cells (DCs), which are powerful antigen-presenting
cells, via a pathway involving nuclear factor-κB( N F - κB)
[200].
Nutritional Values and Anticancer Eﬀects. Marine plants play
an important role to fulﬁll the requirement of food and
nutrition for rectifying the human ailments. Most diets
that are protective against cancer are mainly made up from
foods of plant origin. Higher consumption of several plant
foods probably protects against cancers. The “plant-based”
diets give more emphasis to those plant foods that are high
in nutrients, high in dietary ﬁber (and so in non-starch
polysaccharides), and low in energy density. Non-starchy
vegetables, and fruits, probably protect against some cancers
[201].
Seaweeds are used extensively for human consumption
and theycontainotherinteresting componentsortraditional
medicinal value with curative powers for a variety of diseases
(tuberculosis, arthritis, colds, inﬂuenza, cancer, etc.). Most
people unknowingly utilize seaweed products daily in the
form of processed food items like processed dairy, meat,
and fruit products and domestic commodities like paint,
toothpaste, solid air fresheners, cosmetics, and so forth.
Seaweeds are excellent source of vitamins A, Bl, B12, C, D
& E, riboﬂavin, niacin, pantothenic acid and folic acid 3, 4
as well as minerals such as Ca, P, Na, K. Their amino acid
content is well balanced, containing most of the essential
amino acids needed for life and health. They have more than
54 trace elements required for human body’s physiological
functionsinquantitiesgreatlyexceedingvegetablesandother
land plants [202].
6.Conclusion
Increasing global warming, malnutrition, and various envi-
ronmental insults continue to increase the incidences of
cancer. Accordingto the American CancerSociety,the global
burden is expected to grow as 27 million new cancer cases
and 17.5 million cancer deaths simply due to the growth
and aging of the population by 2050. Natural derivatives
play an important role to prevent the cancer incidences
as synthetic drug formulations cause various harmful side
eﬀects to human beings. Marine ﬂoras are potential source
of anticancer compounds, but they are least explored
(Table 1). Of the anticancer compounds extracted so far,
the marine algae contribute 65.63%, the mangroves 28.12%,12 Journal of Oncology
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Figure 4: Relative contribution of diﬀerent marine ﬂoral compo-
nents to anticancer compounds.
and the bacteria 6.25%, (Figure 4). Owing to a diverse
chemical ecology, the marine organisms especially marine
ﬂora have a great promise for providing potent, cheaper,
and safer anticancer drugs, which deserve an extensive
investigation.
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